ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.042 AUD -2.33%
Market Cap: 85.1m AUD

Intrinsic Value

The intrinsic value of one IPD stock under the Base Case scenario is 0.067 AUD. Compared to the current market price of 0.042 AUD, ImpediMed Ltd is Undervalued by 38%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPD Intrinsic Value
0.067 AUD
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
ImpediMed Ltd

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
IPD
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for IPD cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about IPD?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about ImpediMed Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
ImpediMed Ltd

Current Assets 23.2m
Cash & Short-Term Investments 17.7m
Receivables 3.6m
Other Current Assets 1.9m
Non-Current Assets 16m
Long-Term Investments 51k
PP&E 1.2m
Intangibles 14.7m
Efficiency

Free Cash Flow Analysis
ImpediMed Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
ImpediMed Ltd

Revenue
11.5m AUD
Cost of Revenue
-1.4m AUD
Gross Profit
10.1m AUD
Operating Expenses
-32.4m AUD
Operating Income
-22.3m AUD
Other Expenses
1.1m AUD
Net Income
-21.2m AUD
Fundamental Scores

IPD Profitability Score
Profitability Due Diligence

ImpediMed Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Years Revenue Growth
30/100
Profitability
Score

ImpediMed Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

IPD Solvency Score
Solvency Due Diligence

ImpediMed Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
67/100
Solvency
Score

ImpediMed Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPD Price Targets Summary
ImpediMed Ltd

Wall Street analysts forecast IPD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPD is 0.138 AUD with a low forecast of 0.091 AUD and a high forecast of 0.179 AUD.

Lowest
Price Target
0.091 AUD
116% Upside
Average
Price Target
0.138 AUD
228% Upside
Highest
Price Target
0.179 AUD
325% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

ImpediMed Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for IPD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPD Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one IPD stock?

The intrinsic value of one IPD stock under the Base Case scenario is 0.067 AUD.

Is IPD stock undervalued or overvalued?

Compared to the current market price of 0.042 AUD, ImpediMed Ltd is Undervalued by 38%.

Back to Top